What's got me most excited about ANP, and MD talks about it in his latest ********* interview, is that the Phase II trail in Europe, if successful gives them the right to commercialise (boom!). He goes on to point out that the endpoints for the trial are the same as the endpoints for the US Phase II trial that was successful.
It's no wonder they've secured ex Sarepta bigwigs - they're going to do it all over again.
Where others have failed will Atl1102 succeed ?, page-18
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
-0.010(13.5%) |
Mkt cap ! $57.69M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.6¢ | 5.9¢ | $516.4K | 8.992M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 339429 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 143169 | 1 |
View Market Depth
| Last trade - 16.10pm 25/04/2024 (20 minute delay) ? |
|
|||||
|
Last
5.9¢ |
Change
-0.010 ( 21.3 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.6¢ | 5.9¢ | 132018 | ||
| Last updated 15.49pm 25/04/2024 ? | |||||
| PER (ASX) Chart |